arly trials of B vitamin therapy to lower plasma total homocysteine (tHcy) reported no reduction of stroke with high doses of folate/B6 and cyanocobalamin 400-1,000 µg daily. In patients with diabetic nephropathy, folate/B6 and cyanocobalamin 1,000 µg daily accelerated the decline of renal function and doubled cardiovascular events. Patients with renal failure have high cyanide levels. The French SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids (Su.Fol.OM3) trial-with the best renal function of the early trials and the lowest dose of cyanocobalamin (20 µg daily)-reported a 43% reduction of stroke. Then the China Stroke Primary Prevention Trial (CSPPT) reported that folic acid alone reduced stroke and was beneficial even in patients with impaired renal function. Patient-level data from the Vitamin Intervention to Prevent Stroke (VISP) and VITAmins TO Prevent Stroke (VITATOPS) trials and meta-analyses stratified by renal function and dose of cyanocobalamin confirmed that harm from cyanocobalamin among participants with renal impairment obscured the benefit of B vitamins in the early trials. It does seem that B vitamins reduce the risk of stroke. In the era of folate fortification, B12 is the main nutritional determinant of tHcy, and metabolic B12 deficiency is very common and usually missed. Therefore, folate alone is not the optimal way to lower tHcy: the use of folate (and possibly B6) with methylcobalamin or oxocobalamin should be considered.
Despite substantial evidence to the contrary, there is still a widespread belief that B vitamins to lower plasma total homocysteine (tHcy) do not prevent stroke. This belief is based on the failure of early clinical trials to show a reduction of stroke with B vitamin therapy. However, it is increasingly clear that harm from cyanocobalamin among participants with impaired renal function obscured the benefit of B vitamin therapy in these early trials. Table 1 shows the timeline of the history of B vitamin therapy for stroke prevention by lowering of tHcy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The biological plausibility of the hypothesis that lowering tHcy with vitamin therapy should reduce the risk of stroke was overwhelming. 16 McCully first suggested in 1969 1 that high levels of tHcy may accelerate atherosclerosis based on findings in patients with severe hyperhomocysteinemia in patients homozygous for cystathionine synthase deficiency. In 1986, Boers et al. 2 reported that patients with premature coronary disease were more likely to have high tHcy. By 1997 it was clear that there was a strong, graded increased risk of cardiovascular disease with higher levels of tHcy. 3, 17 There are several mechanisms by which elevated tHcy aggravates cardiovascular disease, and stroke in particular. High levels of homocysteine increase oxidative stress, impair endothelial function and increase thrombosis.
There are several B vitamins that are cofactors in the metabolism of homocysteine, as shown in Figure 1 . 15 It was hypothesized, therefore, that a combination of folic acid and vitamin B12, which catalyze remethylation of homocysteine to methionine, and vitamin B6, which catalyzes transsulfuration to cystathionine, should lower levels of tHcy and thereby reduce cardiovascular events. 18 A series of clinical trials ensued to test that hypothesis.
The first large trial that failed to show benefit of B vitamins was the Vitamin Intervention to Prevent Stroke (VISP) trial, 4 published in 2004. There were several reasons why this trial did not show benefits of B vitamins. Firstly, folate fortification of the grain supply in North America coincided with the 1989 initiation of the trial, thereby negating the benefit of folic acid. Secondly, participants were not randomized to placebo versus active vitamins; they received high-dose B vitamins versus low dose B vitamins, and the low-dose regimen contained the recommended daily intake of vitamin B12 (6 µg daily). Thirdly, participants with a serum B12 below the reference range were given monthly injections of B12, regardless of which arm of the study to which they were randomized, thus preventing the benefit of B12 in the very participants who would have benefited most. 6 and the Heart Outcomes Prevention Evaluation 2 (HOPE-2) trial 7 were published in the same edition of the New England Journal of Medicine. The NORVIT trial showed no benefit of B vitamin therapy, and even showed harm among participants receiving cyanocobalamin. The HOPE-2 trial actually showed a 25% reduction of stroke with B vitamins that was arguably misinterpreted by the authors because they found no reduction of myocardial infarction.
Being cardiologists, and perhaps unaware of the cerebral circulation, they may not have conceived a biological difference between myocardial infarction and stroke, so concluded that the reduction of stroke was a chance finding. However, stroke and myocardial infarction are not the same. Myocardial infarctions are virtually all caused by a plaque rupture with occlusion of a coronary artery; most strokes are due to small vessel disease, or to embolization from the carotid arteries, the aorta, or the heart. High levels of tHcy quadruple the risk of stroke in atrial fibrillation, 19 increase venous thrombosis, and are associated with microemboli in patients with carotid stenosis.
In the same edition of the New England Journal of Medicine, an editorial by Loscalzo 8 hypothesized that the failure to show benefit of B vitamins was due to toxicity from high doses of folic acid. All of this led to the conclusion by most physicians that "homocysteine is dead". High tHcy is demonstrated to be a clear graded risk factor for cardiovascular disease and interacts with smoking. 3 
2004
The VISP trial showed no benefit of high-dose versus low-dose folate/B6/B12 including cyanocobalamin 400 µg daily in the high-dose arm. 4 2005 An analysis of a subgroup of the VISP trial, which excluded participants who received B12 injections and those in the lowest decile of eGFR (48 mL/min/1.73 m 2 ),
showed a 34% reduction of stroke, MI and vascular death when comparing participants with good B12 absorption who received high dose vitamins versus those with lower B12 at baseline who received low-dose vitamins. 5 
2006
The NORVIT trial showed no benefit of B vitamins, and harm in the arm with cyanocobalamin 1,000 µg daily. 6 
The HOPE-2 trial, with better renal function than the earlier trials, showed a 25% reduction of stroke with B folate/B6 and 1,000 µg daily of cyanocobalamin, but reported this as a chance finding because there was no reduction of MI. 7 
Loscalzo hypothesized that the reason for the null results of the trials was high doses of unmetabolized folic acid. 8 
2010
The DIVINe study investigating high dose folate/B6 and 1,000 µg of cyanocobalamin showed harm in patients with diabetic nephropathy, accelerated decline of renal function and a doubling of cardiovascular events; all these events occurred in patients with a GFR <50 mL/min/ . 5 In the remaining subgroup of 2,155 patients, the median baseline serum B12
was 322 pmol/L. Figure 2 shows the result of that study. 5, 15 Participants with a baseline serum B12 above the median (meaning they could absorb B12 well) and who had received high-dose B vitamins had a 34% reduction of stroke, myocardial infarction, and vascular death compared with those whose baseline B12
was below the median and received low-dose vitamins.
In 2010, the Diabetic Intervention with Vitamin in Nephropathy (DIVINe) study was published. Patients with diabetic nephropathy were randomized to high-dose B vitamins, containing folic acid 5 mg, B6 25 mg and cyanocobalamin 1,000 µg daily versus placebo. We found that B vitamins were harmful, accelerating the decline of renal function, and doubling cardiovascular events (Figure 3) . 9 All the events occurred in participants with a glomerular filtration rate of <50 mL/min/1.73 m 2 . 21 After this study, I received emails pointing out that Koyama et al. had reported that patients with renal failure had high levels of thiocyanate. 22 They had also reported that in patients with renal failure, methylcobalamin lowered levels of both tHcy and asymmetric dimethylarginine (ADMA; a nitric oxide antagonist that is an evil companion of homocysteine), 23 whereas in a Norwegian study, cyanocobalamin did not lower levels of ADMA. 24 In 2010, the Australian VITAmins TO Prevent Stroke (VITATOPS) trial reported no benefit of folate/B6 and cyanocobalamin 500 µg daily in the main study; 10 later they reported that B vitamins reduced stroke by 24% in a subgroup that did not receive antiplatelet agents. 13 B6 and B12 and/or OMega-3 fatty acids (Su.Fol.OM3) was published. 11 In this study the dose of cyanocobalamin was only 20 µg daily, and the renal function was much better than in the other studies ( Table 2) . 4, 6, 7, 9, 10, 14, 25, 26 The reduction of stroke was 43%.
In 2011, I hypothesized with Stampfer that harm from cyanocobalamin among study participants with renal impairment had obscured the benefit of B vitamins in the earlier trials. 12 Then in 2015, the final piece of the puzzle fell into place. The China Stroke Primary Prevention Trial (CSPPT) reported that in China, where folate fortification does not exist, folic acid reduced stroke in primary prevention by 25%. 14 In higher-risk patients with low density lipoprotein cholesterol (LDL-C) of >2 mmol/L, folic acid reduced stroke by 30%. 27 Crucially, folic acid was beneficial among study participants with impaired renal function. 28 In 2017, with Yi and Hankey, we performed a meta-analysis of the trials stratified by dose of cynanocobalamin and by renal function. In addition, we analyzed patient-level data from the VISP trial and the VITAPOPS trial. What emerged was that harm from high-dose cyanocobalamin among study participants obscured the benefit of B vitamins among study participants with good renal function. 15 In line with this analysis, it turns out that besides folic acid and possibly vitamin B6, we should perhaps be using methylcobalamin or oxocobalamin, not cyanocobalamin, to prevent stroke. This is important because in the era of folate fortification, B12 is the major determinant of elevated tHcy. 29, 30 Unrecognized metabolic B12 deficiency is very common, and usually missed. 31 Measuring total serum B12 does not accurately assess metabolic adequacy of B12 because a small and variable fraction is active (~6-20%). Thus, among patients with a total serum B12 in the reference range (~60-600 pmol/L), many patients have metabolic B12 deficiency. In order to assess metabolic adequacy of serum B12 it is necessary to measure holotranscobalamin, or one of the metabolites that are elevated in B12 deficiency: methylmalonic acid (MMA), or tHcy. 31 The serum B12 level below which MMA or tHcy begins to rise is 400 pmol/L (Figure 4) . 31, 32 So among patients referred to a stroke prevention clinic, 10% of patients aged below 50 years had metabolic B12 deficiency; above the age of 71 years it was 30%. 33 In our community this appears to be declining as physicians become more aware of the issue.
Conclusion
Based on recent findings, it is now clear that B vitamins to lower homocysteine do prevent stroke. It is possible that this was obscured in the early trials by harm from cyanocobalamin among participants with Spence et al., 2017. 15 
